SCHEMBL4377015

SCHEMBL4377015

COc1ccccc1S(=O)(=O)N1CCC(=NOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
TSHR P16473 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 3/20 0.39
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
MEN1 O00255 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377766 0.88 NR3C1 (0.40) PKMTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4382855 0.88 KMT2A (0.52) TSHRKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL4380941 0.87 CHRM1 (0.39) PKMALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4376961 0.83 PKM (0.50) PKMTSHRKDM4EALDH1A1MAPT
SCHEMBL4393934 0.83 PKM (0.58) PKMTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4391478 0.81 PKM (0.52) PKMTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4381279 0.81 PKM (0.49) PKMKDM4EALDH1A1LMNAMAPT
SCHEMBL4378960 0.81 PKM (0.43) PKMTSHRKDM4EALDH1A1MAPT
SCHEMBL4385272 0.81 PKM (0.54) PKMTSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4380325 0.80 L3MBTL1 (0.35) PKMTSHRALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 PKM 2106/4885TSHR 1691/4885KDM4E 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.